论文部分内容阅读
目的研究低分子肝素治疗缺血性烟雾病的临床疗效及脑血流状况变化情况。方法采用随机原则,将61例成年缺血性烟雾病患者,分为试验组(n=31)和对照组(n=30)。对照组给予抗血小板聚集、改善微循环治疗,治疗组在此基础上加用低分子肝素3 000 U皮下注射,每隔12 h 1次,15 d为1个治疗周期,评价2组的临床疗效、脑血流状况变化情况。结果 2组NIHSS评分较治疗前均显著降低(P<0.05),试验组评分显著低于对照组(P<0.05)。试验组脑血流状况显著优于对照组(P<0.05)。结论低分子肝素能明显的改善脑血流量和临床症状,对于缺血性烟雾病患者是一种安全有效的治疗方法。
Objective To study the clinical efficacy of low molecular weight heparin in the treatment of ischemic moyamoya disease and changes of cerebral blood flow status. Methods According to the principle of randomness, 61 adult patients with ischemic moyamoya disease were divided into experimental group (n = 31) and control group (n = 30). The control group was given anti-platelet aggregation to improve the microcirculation treatment. The treatment group was given hypodermic heparin 3 000 U subcutaneously once every 12 h and 15 d as a treatment cycle to evaluate the clinical efficacy of the two groups , Changes in cerebral blood flow conditions. Results The NIHSS scores of the two groups were significantly lower than those before treatment (P <0.05), and the score of the experimental group was significantly lower than that of the control group (P <0.05). The cerebral blood flow in the experimental group was significantly better than that in the control group (P <0.05). Conclusion Low molecular weight heparin can significantly improve cerebral blood flow and clinical symptoms, which is a safe and effective treatment for patients with ischemic moyamoya disease.